Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG, and Cystic Fibrosis Foundation Therapeutics Inc. Arcturus Therapeutics Ltd. has a strategic collaboration with CureVac AG to jointly discover, develop, and commercialize novel messenger RNA therapeutics. The company was founded in 2013 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARCT
Previous Symbol
CUSIPN/A
Phone858-900-2660
Debt
Debt-to-Equity RatioN/A
Current Ratio2.53
Quick Ratio2.53
Price-To-Earnings
Trailing P/E Ratio-1.44
Forward P/E Ratio-2.68
P/E GrowthN/A
Sales & Book Value
Annual Sales$13 million
Price / Sales4.21
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.20 per share
Price / Book1.59
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees60
Outstanding Shares10,740,000
Market Cap$58.98 million
OptionableOptionable
Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions
What is Arcturus Therapeutics' stock symbol?
Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."
How were Arcturus Therapeutics' earnings last quarter?
Arcturus Therapeutics Ltd (NASDAQ:ARCT) released its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.46) by $0.04. The biotechnology company had revenue of $3.42 million for the quarter, compared to the consensus estimate of $3.75 million. View Arcturus Therapeutics' Earnings History.
When is Arcturus Therapeutics' next earnings date?
What price target have analysts set for ARCT?
4 brokerages have issued 12-month price targets for Arcturus Therapeutics' shares. Their predictions range from $12.00 to $12.00. On average, they expect Arcturus Therapeutics' share price to reach $12.00 in the next year. This suggests a possible upside of 135.3% from the stock's current price. View Analyst Price Targets for Arcturus Therapeutics.
What is the consensus analysts' recommendation for Arcturus Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcturus Therapeutics.
What are Wall Street analysts saying about Arcturus Therapeutics stock?
Here are some recent quotes from research analysts about Arcturus Therapeutics stock:
- 1. According to Zacks Investment Research, "Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA. " (11/19/2018)
- 2. WBB Securities analysts commented, "Mesoblast announced continued positive survival data for remestemcel-L (allogeneic cell therapy) in children with steroid refractory acute graft vs. host disease (aGvHD). The next step for the company is meeting with FDA to discuss BLA submission. The cell therapy is already approved in Japan (as TEMCELL HS Inj) for aGvHD, licensed to JCR Pharmaceuticals Co Ltd (TYO: 4552 – NR)." (9/20/2018)
Has Arcturus Therapeutics been receiving favorable news coverage?
News stories about ARCT stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Arcturus Therapeutics earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Arcturus Therapeutics' key competitors?
Some companies that are related to Arcturus Therapeutics include CELYAD SA/ADR (CYAD), Strongbridge Biopharma (SBBP), Paratek Pharmaceuticals (PRTK), ProMetic Life Sciences (PFSCF), Aduro BioTech (ADRO), Marinus Pharmaceuticals (MRNS), Axovant Sciences (AXON), Lannett (LCI), AcelRx Pharmaceuticals (ACRX), Urovant Sciences (UROV), Aquestive Therapeutics (AQST), Kamada (KMDA), Galectin Therapeutics (GALT), Synlogic (SYBX) and LifeVantage (LFVN).
Who are Arcturus Therapeutics' key executives?
Arcturus Therapeutics' management team includes the folowing people:
- Mr. Joseph E. Payne M.Sc., Founder, CEO, Pres & Director
- Dr. Padmanabh Chivukula, Founder, COO & Chief Scientific Officer
- Mr. Andrew H. Sassine, Interim CFO & Director (Age 54)
- Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance Management
- K. C. Kummerfeld, VP of Fin. & Corp. Controller
Who are Arcturus Therapeutics' major shareholders?
Arcturus Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (7.20%), Worth Venture Partners LLC (0.31%) and JPMorgan Chase & Co. (0.16%).
Which major investors are buying Arcturus Therapeutics stock?
ARCT stock was acquired by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Worth Venture Partners LLC and JPMorgan Chase & Co..
How do I buy shares of Arcturus Therapeutics?
Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arcturus Therapeutics' stock price today?
One share of ARCT stock can currently be purchased for approximately $5.10.
How big of a company is Arcturus Therapeutics?
Arcturus Therapeutics has a market capitalization of $58.98 million and generates $13 million in revenue each year. The biotechnology company earns $-10,900,000.00 in net income (profit) each year or ($3.53) on an earnings per share basis. Arcturus Therapeutics employs 60 workers across the globe.
What is Arcturus Therapeutics' official website?
How can I contact Arcturus Therapeutics?
Arcturus Therapeutics' mailing address is 10628 Science Center Drive Suite 250, San Diego CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]
MarketBeat Community Rating for Arcturus Therapeutics (NASDAQ ARCT)
MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Vote "Outperform" if you believe ARCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
